Drugs / VS-505
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04551300 | Oct 2020 → Jun 2022 | hyperphosphatemia | Shanghai Alebund Pharmaceuticals Limited | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-06-26 | Alebund Pharmaceuticals | Results 礼邦医药宣布 AP301 治疗透析患者高磷血症的关键性 Ⅲ 期研究达到主要疗效终点 alebund.com ↗
该研究达到主要疗效及安全性终点。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | Alebund Pharmaceuticals | 礼邦医药在 2025 年美国肾脏病年会上公布其磷结合剂 AP301 的 Ⅲ 期临床试验数据 alebund.com ↗ |
| 2025-06-26 | Alebund Pharmaceuticals | 礼邦医药宣布 AP301 治疗透析患者高磷血症的关键性 Ⅲ 期研究达到主要疗效终点 alebund.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VS-505 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04551300 ↗ |
| Known as | AP301 | “VS-505 (AP301), an acacia and ferric oxyhydroxide polymer” PMID 38453435 ↗ Sep 2024 |
| Modality | Other / unclassified | “an acacia and ferric oxyhydroxide polymer” PMID 38453435 ↗ Sep 2024 |
| Route | Oral | “oral VS-505 administered three times daily with meals” PMID 38453435 ↗ Sep 2024 |